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With growing proof of efficacy in varied indications, regenerative medicine has reached a positive inflection point 
in the investment of time and money by established industry leaders and disruptive startups. With rapid growth 
comes the need to devote resources to the engineering challenges that currently prevent the quick and cost-
effective manufacture of therapies that maintain a consistent, high-level of quality and, in turn, can support 
commercial manufacturing. This is especially true when looking at patient specific cell therapies that require 
rapid change over of equipment and benefit little from traditional sterile barriers (i.e. filters and heat inactivation). 
Counter-flow centrifugation (CFC) presents an intriguing technology that, when implemented using closed and 
automated system, provides a platform for upstream and downstream processing of cellular therapies by 
incorporating multiple unit processes and mitigating the risk imposed with manual equipment transfers.  
 
The CFC technology under development by a partnership Hitachi Chemical Advanced Therapeutic Solutions 
(HCATS) and Invetech compounds the benefits of a fully integrated, closed processing kit with easily 
customizable procedures to integrate multiple unit processes onto a singular device. Increased integration of 
unit processes will be integral to addressing the dynamic challenges of commercial cell therapy manufacturing in 
a scaled-out model. This CFC device has shown the capability to perform platelet wash steps with 99% 
efficiency and retain 100% of the mononuclear cells. The platform can then harvest a concentrated volume of 
cells or shift directly into an elutriation protocol to separate hematopoietic cell populations. Further development 
work is being done to create a CAR-T manufacturing protocol using the device and to establish fill/finish 
capabilities. By incorporating multiple unit processes onto a device that also meets the need for rapid change-





Figure 1. Image of performing a platelet wash on an incoming apheresis collection using counter-flow 
centrifugation. 
 
 
 
